(Q34182053)

31 July 2017

1 reference

title

Replicating herpes simplex virus vectors for cancer gene therapy (English)

1 reference

31 July 2017

0 references

0 references

1 reference

Yeung SN

1

1 reference

PubMed ID

11249507

31 July 2017

Tufaro F

series ordinal

2

1 reference

PubMed ID

11249507

31 July 2017

language of work or name

English

0 references

publication date

1 May 2000

1 reference

Expert Opinion on Pharmacotherapy

31 July 2017

1 reference

31 July 2017

1

1 reference

31 July 2017

4

1 reference

31 July 2017

623-631

1 reference

The bystander effect in the HSVtk/ganciclovir system and its relationship to gap junctional communication

31 July 2017

1 reference

https://api.crossref.org/works/10.1517%2F14656566.1.4.623

In situ delivery of suicide genes for cancer treatment.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.1.4.623

The cell-surface heparan sulfate proteoglycan glypican-1 regulates growth factor action in pancreatic carcinoma cells and is overexpressed in human pancreatic cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.1.4.623

Oligosaccharide sequence of human breast cancer cell heparan sulfate with high affinity for laminin

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.1.4.623

Heparan sulfate undergoes specific structural changes during the progression from human colon adenoma to carcinoma in vitro.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.1.4.623

Attenuated multi–mutated herpes simplex virus–1 for the treatment of malignant gliomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.1.4.623

Treatment of human breast cancer in a brain metastatic model by G207, a replication-competent multimutated herpes simplex virus 1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.1.4.623

Systemic antitumor immunity in experimental brain tumor therapy using a multimutated, replication-competent herpes simplex virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.1.4.623

Herpes simplex virus as an in situ cancer vaccine for the induction of specific anti-tumor immunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.1.4.623

Effect of prior exposure to herpes simplex virus 1 on viral vector-mediated tumor therapy in immunocompetent mice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.1.4.623

Corticosteroid administration does not affect viral oncolytic activity, but inhibits antitumor immunity in replication-competent herpes simplex virus tumor therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.1.4.623

Herpes simplex virus type 1 deletion variants 1714 and 1716 pinpoint neurovirulence-related sequences in Glasgow strain 17+ between immediate early gene 1 and the 'a' sequence

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.1.4.623

Local and systemic therapy of human prostate adenocarcinoma with the conditionally replicating herpes simplex virus vector G207.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.1.4.623

Enhancement of replication of genetically engineered herpes simplex viruses by ionizing radiation: a new paradigm for destruction of therapeutically intractable tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.1.4.623

Replication-competent herpes simplex virus vector G207 and cisplatin combination therapy for head and neck squamous cell carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.1.4.623

21 January 2018

Identifiers

DOI

10.1517/14656566.1.4.623

1 reference

31 July 2017

1 reference

PubMed ID

11249507